Menu
You have to log in or sign up before you can proceed.
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

News

Puma Biotechnology to Host Conference Call to Discuss First Quarter Financial Results: https://mms.businesswire.com/media/20191106005906/en/305625/5/puma_logo_JPEG.jpg
Puma Biotechnology to Host Conference Call to Discuss First Quarter Financial Results


Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.m. PDT/4:30 p.m. EDT on Thursday, May 5, 2022, following the release of its first quarter

Annual General Meeting - Shareholders approve all proposals of the Board of Directors
Annual General Meeting - Shareholders approve all proposals of the Board of Directors
Annual General Meeting - Shareholders approve all proposals of the Board of Directors
Simulations Plus Enters New Collaboration to Advance DDDPlus™ Software: https://mms.businesswire.com/media/20200318005128/en/780378/5/BusinessWireLogo.jpg
Simulations Plus Enters New Collaboration to Advance DDDPlus™ Software


Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemical, and consumer goods industries, today announced a new

Lysogene Publishes Positive Preliminary Preclinical Results in the Treatment of Fragile X Syndrome: https://mms.businesswire.com/media/20220412005891/en/1418496/5/Lysogene_-_Logo.jpg
Lysogene Publishes Positive Preliminary Preclinical Results in the Treatment of Fragile X Syndrome


Regulatory News:



Lysogene (FR0013233475 – LYS), a phase 3 gene therapy platform Company targeting central nervous system (CNS) diseases, announced today the publication of a peer-reviewed article

Sensorion Will Participate in Chardan’s 6th Annual Genetic Medicines and Cell Therapy Manufacturing Summit Held Virtually on April 26, 2022: https://mms.businesswire.com/media/20210609005851/en/705797/5/logo-sensorion2.jpg
Sensorion Will Participate in Chardan’s 6th Annual Genetic Medicines and Cell Therapy Manufacturing Summit Held Virtually on April 26, 2022


Regulatory News:



Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and

DGAP-News: MPH Health Care AG: Preliminary IFRS result 2021
DGAP-News: MPH Health Care AG: Preliminary IFRS result 2021
DGAP-News: MPH Health Care AG: Preliminary IFRS result 2021
Kuros Biosciences's MagnetOs Flex Matrix Cleared by FDA for Spinal Indications
Kuros Biosciences's MagnetOs Flex Matrix Cleared by FDA for Spinal Indications
Kuros Biosciences's MagnetOs Flex Matrix Cleared by FDA for Spinal Indications
DGAP-News: Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. to Report Full Year 2021 Financial Results and Operational Progress on April 28, 2022
DGAP-News: Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. to Report Full Year 2021 Financial Results and Operational Progress on April 28, 2022
DGAP-News: Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. to Report Full Year 2021 Financial Results and Operational Progress on April 28, 2022
DGAP-News: MicroVision Inc.: MicroVision to Announce First Quarter 2022 Results on April 27, 2022
DGAP-News: MicroVision Inc.: MicroVision to Announce First Quarter 2022 Results on April 27, 2022
DGAP-News: MicroVision Inc.: MicroVision to Announce First Quarter 2022 Results on April 27, 2022
QIAGEN N.V. to release results for Q1 2022 and hold Webcast
QIAGEN N.V. to release results for Q1 2022 and hold Webcast


QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) announced today that it plans to release results for the first quarter of 2022 on Wednesday, April 27, at approximately 22:05 Frankfurt time

Clovis Oncology to Announce First Quarter 2022 Financial Results and Host Webcast Conference Call on May 4: https://mms.businesswire.com/media/20191107005162/en/305545/5/Clovis_Logo_Process_Color.jpg
Clovis Oncology to Announce First Quarter 2022 Financial Results and Host Webcast Conference Call on May 4


Clovis Oncology, Inc. (NASDAQ: CLVS) will announce its first quarter 2022 financial results on Wednesday, May 4, 2022, before the open of the US financial markets. Clovis’ senior management will

STAAR Surgical to Report First Quarter Results on May 4, 2022: https://mms.businesswire.com/media/20200413005098/en/683092/5/STAAR_Surgical_Logo_Primary_Lockup_%28Sunise_Teal%29.jpg
STAAR Surgical to Report First Quarter Results on May 4, 2022


STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, today announced that it will release

Navidea Biopharmaceuticals Announces Updated Third-Party Asset Valuation of Tc99m Tilmanocept for Indications in Rheumatoid Arthritis for U.S. and EU Markets: https://mms.businesswire.com/media/20191107006076/en/389794/5/navidea_cmyk.jpg
Navidea Biopharmaceuticals Announces Updated Third-Party Asset Valuation of Tc99m Tilmanocept for Indications in Rheumatoid Arthritis for U.S. and EU Markets


Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today

Navidea Biopharmaceuticals Announces Positive Preliminary Results of Its Ongoing Phase 2B Study Comparing Tc99m Tilmanocept Imaging with Histopathology of Joints from Patients with Rheumatoid Arthritis: https://mms.businesswire.com/media/20191107006076/en/389794/5/navidea_cmyk.jpg
Navidea Biopharmaceuticals Announces Positive Preliminary Results of Its Ongoing Phase 2B Study Comparing Tc99m Tilmanocept Imaging with Histopathology of Joints from Patients with Rheumatoid Arthritis


Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today

DGAP-News: Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. to Participate at Upcoming  Investor Conferences
DGAP-News: Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. to Participate at Upcoming Investor Conferences
DGAP-News: Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. to Participate at Upcoming Investor Conferences
Evolva achieves important product-related milestones with global customer, triggering revenues of more than 20% of FY21 total revenues
Evolva achieves important product-related milestones with global customer, triggering revenues of more than 20% of FY21 total revenues
Evolva achieves important product-related milestones with global customer, triggering revenues of more than 20% of FY21 total revenues
Novocure Hosts Ceremonial Groundbreaking with New Hampshire Governor Chris Sununu: https://mms.businesswire.com/media/20191120005453/en/721126/5/novocure_main%405x.jpg
Novocure Hosts Ceremonial Groundbreaking with New Hampshire Governor Chris Sununu


Today, Governor Chris Sununu (R-NH) joined Novocure for a ceremonial event commemorating the start of construction of its new flagship facility in the heart of downtown Portsmouth, New Hampshire

Pfizer Invites Shareholders to Attend Virtual-Only 2022 Annual Meeting of Shareholders on April 28http://www.flickr.com/photos/w0ahitslo/6955091156/sizes/z/in/photostream/: All rights reserved by Queen Beuaroo
Pfizer Invites Shareholders to Attend Virtual-Only 2022 Annual Meeting of Shareholders on April 28


Pfizer Inc. (NYSE: PFE) announced today that its shareholders and the general public are invited to access its virtual-only 2022 Annual Meeting of Shareholders at 9:00 a.m. EDT on Thursday, April

Simulations Plus to Present at the Berenberg Discover AI Seminar: https://mms.businesswire.com/media/20200318005128/en/780378/5/BusinessWireLogo.jpg
Simulations Plus to Present at the Berenberg Discover AI Seminar


Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that management will be

Aurinia Announces Year-Two Commitment to Patient Navigation Grant Program to Address Barriers for Individuals Living with Lupus and Lupus Nephritis: https://mms.businesswire.com/media/20191107005278/en/707846/5/Aurinia-logo-web-700px.jpg
Aurinia Announces Year-Two Commitment to Patient Navigation Grant Program to Address Barriers for Individuals Living with Lupus and Lupus Nephritis


Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today, affirmed its commitment to individuals living with the systemic lupus erythematosus (SLE) and lupus nephritis (LN)

Navidea Biopharmaceuticals Announces the Notice of Allowance for U.S. Patent Application for Diagnosis and Treatment of Leishmaniasis: https://mms.businesswire.com/media/20191107006076/en/389794/5/navidea_cmyk.jpg
Navidea Biopharmaceuticals Announces the Notice of Allowance for U.S. Patent Application for Diagnosis and Treatment of Leishmaniasis


Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today

Hardman & Co Research: Tissue Regenix (TRX) On pathway to sustainability
Hardman & Co Research: Tissue Regenix (TRX) On pathway to sustainability
Hardman & Co Research: Tissue Regenix (TRX) On pathway to sustainability
Navidea Biopharmaceuticals Announces the Regulatory Approval of Lymphoaim in India: https://mms.businesswire.com/media/20191107006076/en/389794/5/navidea_cmyk.jpg
Navidea Biopharmaceuticals Announces the Regulatory Approval of Lymphoaim in India


Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today

Humana’s Impact Report Focuses on Building Trust and Transparency in Journey to Health Equity: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24514/Humana_logo.png
Humana’s Impact Report Focuses on Building Trust and Transparency in Journey to Health Equity


Humana Inc. (NYSE: HUM), one of the nation’s leading health and well-being companies, released its 2021 Impact Report, which highlights the company’s continued commitment to its Environment